Your browser doesn't support javascript.
loading
Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study.
Brito-Zerón, Pilar; Flores-Chávez, Alejandra; Horváth, Ildiko Fanny; Rasmussen, Astrid; Li, Xiaomei; Olsson, Peter; Vissink, Arjan; Priori, Roberta; Armagan, Berkan; Hernandez-Molina, Gabriela; Praprotnik, Sonja; Quartuccio, Luca; Inanç, Nevsun; Özkiziltas, Burcugül; Bartoloni, Elena; Sebastian, Agata; Romão, Vasco C; Solans, Roser; Pasoto, Sandra G; Rischmueller, Maureen; Galisteo, Carlos; Suzuki, Yasunori; Trevisani, Virginia Fernandes Moça; Fugmann, Cecilia; González-García, Andrés; Carubbi, Francesco; Jurcut, Ciprian; Shimizu, Toshimasa; Retamozo, Soledad; Atzeni, Fabiola; Hofauer, Benedikt; Melchor-Díaz, Sheila; Gheita, Tamer; López-Dupla, Miguel; Fonseca-Aizpuru, Eva; Giacomelli, Roberto; Vázquez, Marcos; Consani, Sandra; Akasbi, Miriam; Nakamura, Hideki; Szántó, Antónia; Farris, A Darise; Wang, Li; Mandl, Thomas; Gattamelata, Angelica; Kilic, Levent; Pirkmajer, Katja Perdan; Abacar, Kerem; Tufan, Abdurrahman; de Vita, Salvatore.
Afiliação
  • Brito-Zerón P; Autoimmune Diseases Unit, Research and Innovation Group in Autoimmune Diseases, Sanitas Digital Hospital, Hospital-CIMA-Centre Mèdic Milenium Balmes Sanitas, Barcelona, Spain.
  • Flores-Chávez A; Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Barcelona, Spain.
  • Horváth IF; Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Rasmussen A; Genes and Human Disease Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
  • Li X; Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China(Anhui Provincial Hosipital), Hefei, China.
  • Olsson P; Department of Rheumatology, Skane University Hospital Malmö, Lund University, Lund, Sweden.
  • Vissink A; Department of Oral and Maxillofacial Surger, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
  • Priori R; Department of Internal Medicine and Medical Specialties, Rheumatology Clinic, Sapienza University of Rome, Rome, Italy.
  • Armagan B; Saint Camillus International University of Health Science, UniCamillus, Rome, Italy.
  • Hernandez-Molina G; Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey.
  • Praprotnik S; Immunology and Rheumatology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico.
  • Quartuccio L; Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia.
  • Inanç N; Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy.
  • Özkiziltas B; Marmara University, School of Medicine, Istanbul, Turkey.
  • Bartoloni E; Division of Rheumatology, Department of Internal Medicine, Gazi University School of Medicine, Ankara, Turkey.
  • Sebastian A; Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy.
  • Romão VC; Department of Rheumatology and Internal Medicine, Wroclaw Medical Hospital, Wroclaw, Poland.
  • Solans R; Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte and Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon Academic Medical Centre, Lisbon, Portugal.
  • Pasoto SG; Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain.
  • Rischmueller M; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
  • Galisteo C; Department of Rheumatology, The Queen Elizabeth Hospital, Discipline of Medicine, University of Adelaide, South Australia, Australia.
  • Suzuki Y; Department of Rheumatology, Hospital Parc Taulí, Barcelona, Spain.
  • Trevisani VFM; Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
  • Fugmann C; Division of Health Based Evidence, Federal University of São Paulo, Sao Paulo, Brazil.
  • González-García A; Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Carubbi F; Department of Rheumatology, Hospital 12 de Octubre, Madrid, Spain.
  • Jurcut C; Internal Medicine and Nephrology Unit, Department of Medicine, ASL Avezzano-Sulmona-L'Aquila, San Salvatore Hospital, L'Aquila, Italy.
  • Shimizu T; Department of Internal Medicine, Carol Davila Central Military Emergency Hospital, Bucharest, Romania.
  • Retamozo S; Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Atzeni F; Department of Rheumatology, Hospital Quirón Salud, Barcelona, Spain.
  • Hofauer B; IRCCS Galeazzi Orthopedic Institute, Milan and Rheumatology Unit, University of Messina, Messina, Italy.
  • Melchor-Díaz S; Otorhinolaryngology, Head and Neck Surgery, Technical University Munich, Munich, Germany.
  • Gheita T; Department of Rheumatology, Hospital 12 de Octubre, Madrid, Spain.
  • López-Dupla M; Rheumatology Department, Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt.
  • Fonseca-Aizpuru E; Department of Internal Medicine, Hospital Joan XXIII, Tarragona, Spain.
  • Giacomelli R; Department of Internal Medicine, Hospital de Cabueñes, Gijón, Spain.
  • Vázquez M; Clinical Unit of Rheumatology, University of l'Aquila, School of Medicine, L'Aquila, Italy.
  • Consani S; Department of Rheumatology, Hospital de Clínicas, San Lorenzo, Paraguay.
  • Akasbi M; Internal Medicine, Hospital Maciel, and Universidad de la República (UdelaR), Montevideo, Uruguay.
  • Nakamura H; Department of Internal Medicine, Hospital Infanta Leonor, Madrid, Spain.
  • Szántó A; Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Oyaguchi Kami-cho, Itabashi-ku, Tokyo, Japan.
  • Farris AD; Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Wang L; Genes and Human Disease Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
  • Mandl T; Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China(Anhui Provincial Hosipital), Hefei, China.
  • Gattamelata A; Department of Rheumatology, Skane University Hospital Malmö, Lund University, Lund, Sweden.
  • Kilic L; Department of Internal Medicine and Medical Specialties, Rheumatology Clinic, Sapienza University of Rome, Rome, Italy.
  • Pirkmajer KP; Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey.
  • Abacar K; Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia.
  • Tufan A; Marmara University, School of Medicine, Istanbul, Turkey.
  • de Vita S; Division of Rheumatology, Department of Internal Medicine, Gazi University School of Medicine, Ankara, Turkey.
EClinicalMedicine ; 61: 102062, 2023 Jul.
Article em En | MEDLINE | ID: mdl-37457113
ABSTRACT

Background:

What baseline predictors would be involved in mortality in people with primary Sjögren syndrome (SjS) remains uncertain. This study aimed to investigate the baseline characteristics collected at the time of diagnosis of SjS associated with mortality and to identify mortality risk factors for all-cause death and deaths related to systemic SjS activity measured by the ESSDAI score.

Methods:

In this international, real-world, retrospective, cohort study, we retrospectively collected data from 27 countries on mortality and causes of death from the Big Data Sjögren Registry. Inclusion criteria consisted of fulfilling 2002/2016 SjS classification criteria, and exclusion criteria included chronic HCV/HIV infections and associated systemic autoimmune diseases. A statistical approach based on a directed acyclic graph was used, with all-cause and Sjögren-related mortality as primary endpoints. The key determinants that defined the disease phenotype at diagnosis (glandular, systemic, and immunological) were analysed as independent variables.

Findings:

Between January 1st, 2014 and December 31, 2023, data from 11,372 patients with primary SjS (93.5% women, 78.4% classified as White, mean age at diagnosis of 51.1 years) included in the Registry were analysed. 876 (7.7%) deaths were recorded after a mean follow-up of 8.6 years (SD 7.12). Univariate analysis of prognostic factors for all-cause death identified eight Sjögren-related variables (ocular and oral tests, salivary biopsy, ESSDAI, ANA, anti-Ro, anti-La, and cryoglobulins). The multivariate CPH model adjusted for these variables and the epidemiological features showed that DAS-ESSDAI (high vs no high HR = 1.68; 95% CI, 1.27-2.22) and cryoglobulins (positive vs negative HR = 1.72; 95% CI, 1.22-2.42) were independent predictors of all-cause death. Of the 640 deaths with available information detailing the specific cause of death, 14% were due to systemic SjS. Univariate analysis of prognostic factors for Sjögren-cause death identified five Sjögren-related variables (oral tests, clinESSDAI, DAS-ESSDAI, ANA, and cryoglobulins). The multivariate competing risks CPH model adjusted for these variables and the epidemiological features showed that oral tests (abnormal vs normal

results:

HR = 1.38; 95% CI, 1.01-1.87), DAS-ESSDAI (high vs no high HR = 1.55; 95% CI, 1.22-1.96) and cryoglobulins (positive vs negative HR = 1.52; 95% CI, 1.16-2) were independent predictors of SjS-related death.

Interpretation:

The key mortality risk factors at the time of SjS diagnosis were positive cryoglobulins and a high systemic activity scored using the ESSDAI, conferring a 2-times increased risk of all-cause and SjS-related death. ESSDAI measurement and cryoglobulin testing should be considered mandatory when an individual is diagnosed with SjS.

Funding:

Novartis.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Mortalidade / Geral Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: EClinicalMedicine Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Temas: Mortalidade / Geral Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: EClinicalMedicine Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha